Comparative Pharmacology
Head-to-head clinical analysis: GENOPTIC versus PAROMOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOPTIC versus PAROMOMYCIN SULFATE.
GENOPTIC vs PAROMOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Paromomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in susceptible bacteria. It also has direct amebicidal activity against Entamoeba histolytica by inhibiting protein synthesis.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
25-35 mg/kg/day orally in 3 divided doses for 5-10 days for intestinal amebiasis; 1 g orally every 8 hours for 7 days for cryptosporidiosis.
None Documented
None Documented
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
Terminal elimination half-life: 2–3 hours in normal renal function; extends to 24–48 hours or longer in severe renal impairment, necessitating dose adjustment.
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of absorbed dose excreted in urine within 24 hours; negligible biliary/fecal elimination.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic